Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elafibranor 80 mg single-arm Phase III study in Japanese adults with primary biliary cholangitis
jRCT2011240053Phase 3Active, not recruiting
- Sponsor
- Ipsen
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of elafibranor in primary biliary cholangitis (PBC), sponsored by Ipsen. Primary endpoint: Primary efficacy endpoint. Started Mar 2025; status: active, not recruiting.
02
Drugs
elafibranor
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on jRCT2011240053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011240053.